[Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations].
Ji-Sung JangAmy Junghyun LeeKye Jin ParkKyoung Won KimHyo Jung ParkPublished in: Journal of the Korean Society of Radiology (2023)
In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response. Castration-resistant prostate cancer refers to the state wherein the cancer continues to progress despite a significant reduction of the sex hormone level and is associated with frequent distant metastasis. The Prostate Cancer Working Group 3 (PCWG3) released guidelines that aimed to standardize the assessment of treatment effects in castration-resistant prostate cancer using bone scintigraphy. However, these guidelines can be challenging to comprehend and implement in practical settings. The purpose of this review was to provide an overview of a specific image acquisition method and treatment response assessment for bone scintigraphy-based evaluation of bone lesions in metastatic castration-resistant prostate cancer, in accordance with the PCWG3 guidelines.
Keyphrases
- prostate cancer
- bone mineral density
- soft tissue
- clinical trial
- clinical practice
- bone loss
- squamous cell carcinoma
- small cell lung cancer
- radical prostatectomy
- bone regeneration
- postmenopausal women
- computed tomography
- magnetic resonance
- magnetic resonance imaging
- lymph node
- risk factors
- young adults
- combination therapy